Use of Esketamine Nasal Spray in Patients with Treatment‐Resistant Depression in Routine Practice: A Real‐World French Study

Depression and Anxiety, Год журнала: 2024, Номер 2024(1)

Опубликована: Янв. 1, 2024

The efficacy and safety of esketamine nasal spray (ESK) were established in registration trials patients with treatment-resistant depression (TRD). This French real-world study aimed to describe the treatment patterns, effectiveness, ESK TRD over a 12-month follow-up. used secondary data from patient files hospital-based psychiatrists started during first early access ESK. response remission rates analyzed using total score Montgomery-Åsberg Depression Rating Scale (MADRS). time work resumption described (Kaplan-Meier method). Adverse events (AEs) analyzed. Prior initiation, 157 (age ≤ 65 years, 82.8%; female, 66.2%) had for 10.5 years (median, IQR, 4.2-21.2) received median 6 (3-8) previous lines. At mean ± SD MADRS was 32.1 7.7. that time, combined antidepressants (93.6% patients; SNRI, 65.0%; SSRI, 57.3%) and/or other potentiation strategy (63.1%; atypical antipsychotics, 36.3%; lithium, 25.6%; antiepileptics, 21.7%). During follow-up, 125 (79.6%) discontinued duration 19.4 weeks (IQR, 4.4-40.1). 1 month after 40.2% still treated met criteria clinical 19.7% (median response, 5.7 weeks; 95% CI (4.1-8.4)). 82.6% active on sick leave at initiation; rate 24% (13%-40%) 12 later. AEs reported 68.6% patients, serious 17.2%, leading discontinuation 14.6%. These effectiveness consistent findings trials, describing real-life experience receiving confirming has its place therapy TRD.

Язык: Английский

---

Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment

Journal of Psychopharmacology, Год журнала: 2024, Номер unknown

Опубликована: Авг. 7, 2024

Background: Treatment-resistant depression (TRD) is defined as the failure of at least two antidepressants in adequate doses and timing during a major depressive episode. Esketamine intranasal (ESK-IN) has been approved by Food Drug Administration European Medicines Agency for treatment TRD combination with other antidepressants. Aims: To assess effectiveness tolerability sample patients who received ESK-IN part compassionate use program. Methods: A retrospective, observational study was carried out on diagnosis enrolled early access program nine centers. Effectiveness assessed Montgomery-Asberg rating scale (MADRS) four time points: baseline, 28, 90, 180 days treatment. Results: The included 71 (70% women) mean baseline MADRS score 38.27 ± 5.9 total or partial work disability rates 85%. associated statistically clinically significant reduction severity symptoms all points assessed. presence side effects common but majority were mild resolved after observation period. Those psychotherapy showed significantly lower 90 than those did not undergo psychotherapy. Conclusion: proven to be effective safe clinical severe TRD. optimize outcomes, pharmacological should always integrated into comprehensive therapeutic plan that encompasses strategies such psychotherapy, social support, family interventions.

Язык: Английский

---

Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective

Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2024, Номер unknown, С. 111213 - 111213

Опубликована: Дек. 1, 2024

Язык: Английский

---

Oral ketamine may offer a solution to the ketamine conundrum

Psychopharmacology, Год журнала: 2023, Номер 240(12), С. 2483 - 2497

Опубликована: Окт. 26, 2023

Abstract Ketamine has received considerable attention for its rapid and robust antidepressant response over the past decade. Current evidence, in clinical populations, predominantly relates to parenterally administered ketamine, which is reported produce significant undesirable side effects, with additional concerns regarding long-term safety abuse potential. Attempts a similar drug without psychotomimetic have proved elusive. Orally ketamine different pharmacological profile parentally suggesting it may be viable alternative. Emerging evidence efficacy tolerability of oral suggests that favourable route administration, as appears obtain similarly beneficial treatment but cost medical resources required parenteral dosing. The effects due active metabolite norketamine, been found at substantially higher levels via dosing, most likely first-pass clearance. Despite bioavailability peak plasma concentrations both being lower than when parenterally, low-dose clinically effective treating pain. This also actions norketamine therefore, relevance mental health context explored this narrative review.

Язык: Английский

---

Exploring the potential of Esketamine in the treatment of bipolar depression

European Neuropsychopharmacology, Год журнала: 2023, Номер 77, С. 21 - 23

Опубликована: Сен. 4, 2023

Язык: Английский

---